Skip to main
CLBT

CLBT Stock Forecast & Price Target

CLBT Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cellebrite DI is poised for future success, with a strong market position and high potential for growth through recent acquisitions and expanding product offerings. However, competition and potential challenges related to privacy concerns and extended sales cycles may present obstacles for the company. Despite these challenges, they have shown strong financial performance and have a positive outlook on EBITDA margin and free cash flow. Their recent acquisition and FedRAMP authorization could drive even further growth in the future.

Bears say

Cellebrite DI is heavily reliant on law enforcement and government agencies for the majority of its revenue, which subjects the company to potential budget cycles, sanctions, and decline in government spending that could impact future growth. The company also faces intense competition in its market, which could lead to pricing pressure and loss of market share. Moreover, changes in public sentiment and perceptions of privacy could also affect the company's market opportunity. Additionally, there is a risk of a data breach, which could result in reputational, financial, and legal consequences for the company.

CLBT has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cellebrite DI Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cellebrite DI Ltd (CLBT) Forecast

Analysts have given CLBT a Strong Buy based on their latest research and market trends.

According to 5 analysts, CLBT has a Strong Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cellebrite DI Ltd (CLBT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.